Clinical Trials on Protein-Losing Enteropathies in Russian Federation

Total 147 results

Federal State Budgetary Institution, V. A. Almazov...

Enrolling by invitation

Original Protocol of Oral Cavity Care During Long-term Mechanical Ventilation

Adult Patients of Intensive Care Units on Long-term Lung Mechanical Ventilation

Russian Federation
National Research Center for Hematology, Russia

Unknown

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis (MSC-CY)

Leukemia | Multiple Myeloma

Russian Federation
Samara State Medical University

Enrolling by invitation

Research of the Long-COVID-19 Syndrome in the Children

Long COVID

Russian Federation
The League of Clinical Research, Russia

Completed

Health Related Quality of Life of Youth and Young Adults With Haemophilia A (RELOQ)

Hemophilia A

Russian Federation
St. Petersburg State Pavlov Medical University

Active, not recruiting

ASCT With Nivolumab in Patients With Multiple Myeloma

Multiple Myeloma

Russian Federation
Ivan S Moiseev

Terminated

The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood

Myeloma Multiple

Russian Federation
Celgene

Completed

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

Multiple Myeloma

Russian Federation
N.N. Petrov National Medical Research Center of...

Recruiting

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) (VAB)

Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB

Russian Federation
Recoly N.V.

Completed

Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.

Haemophilia A

Russian Federation
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma

China, Russian Federation
Bayer

Completed

Russian Kogenate Pediatric Study

Hemophilia A

Russian Federation
Ascension Healthcare Development Limited

Recruiting

A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip

Hemophilia A With Inhibitor

Russian Federation
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Bulgaria, Russian Federation
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
CSL Behring
Parexel

Completed

Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Poland, Russian Federation, Ukraine
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
Catalyst Biosciences

Completed

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Hemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

Bulgaria, Russian Federation
Biocad

Recruiting

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma (DARVIVA)

Multiple Myeloma

Russian Federation
CSL Behring

Completed

Extension Study of Biostate in Subjects With Von Willebrand Disease

Von Willebrand Disease

Bulgaria, Germany, Poland, Russian Federation, Ukraine
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
CSL Behring

Terminated

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Hemophilia A

Russian Federation, Germany, Italy, Austria, Greece
Biocad

Recruiting

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Hemophilia B

Russian Federation
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Takeda

Completed

A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A (HAPKIDO)

Hemophilia A

Russian Federation
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Baxalta now part of Shire

Completed

BAX 326 Pediatric Study

Hemophilia B

Russian Federation, Ukraine, India, Poland, Romania, United Kingdom
Octapharma

Active, not recruiting

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Von Willebrand Disease

United States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Neoplasm

United States, Belgium, Russian Federation
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Octapharma

Completed

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Von Willebrand Diseases

Lebanon, Croatia, United States, Belarus, Bulgaria, Hungary, Russian Federation, Ukraine
Genzyme, a Sanofi Company

Completed

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Hemophilia A | Hemophilia B

Bulgaria, United States, United Kingdom, Russian Federation, Switzerland
Sanofi

Completed

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

Hemophilia A | Hemophilia B

Bulgaria, Switzerland, United Kingdom, United States, Russian Federation
Janssen-Cilag International NV

Terminated

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Multiple Myeloma

Poland, Turkey, Russian Federation, Hungary, Lithuania, Croatia, Germany
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Bayer

Completed

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Hemophilia A

Croatia, Germany, Saudi Arabia, Kazakhstan, Romania, Russian Federation, Slovenia, Bahrain, United Arab Emirates, Bosnia and Herzegovina, Israel, Kuwait, Libyan Arab Jamahiriya, Morocco, Oman, Qatar, Tunisia
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
Octapharma

Completed

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Congenital Fibrinogen Deficiency

United States, Bulgaria, India, Iran, Islamic Republic of, Lebanon, Russian Federation, Saudi Arabia, Turkey, United Kingdom
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
Gilead Sciences

Terminated

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States, Czech Republic, Russian Federation
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
rEVO Biologics
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

United States, Bulgaria, Poland, Russian Federation, Belarus, Georgia, Israel, Romania, Ukraine, United Kingdom
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine

Clinical Trials on Protein-Losing Enteropathies in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations